Tirzepatide, AKA Mounjaro: the drug, the brand, and what it does

Why tirzepatide's trial data matters, and what the numbers actually showed

SURMOUNT-1, published in the New England Journal of Medicine, enrolled 2,539 adults with obesity or overweight alongside at least one weight-related condition, excluding type 2 diabetes. Over 72 weeks, those on the 15 mg dose lost an average of roughly 20–21% of their starting body weight. That is not a marketing figure; it is the primary outcome of a randomised, double-blind, placebo-controlled trial.

There is a misconception worth clearing up gently: some people assume these results are about everyone who takes the medicine, no matter how it is used. The trial participants were in a structured programme with diet, activity and regular follow-up support woven in. Weight loss outside that context varies, and no result can be guaranteed for any individual. The evidence is strong; it is not a promise.

SURMOUNT-5, a head-to-head comparison published in 2025, found tirzepatide produced greater average weight reduction than semaglutide 2.4 mg over 72 weeks in adults without diabetes. NICE reviewed this evidence and others when appraising tirzepatide; their assessment is that the data support recommendation for eligible adults with significant weight-related health conditions.

The two names and the single reason behind them

Pharmaceutical convention keeps chemical names and brand names separate. Tirzepatide is the International Nonproprietary Name, the same in every country and language. Mounjaro is the brand Eli Lilly chose for the UK market, and you will see it on the pen, the patient leaflet and the pharmacy label, while tirzepatide appears on clinical study reports, NICE guidance, NHS pages and the BNF. They are interchangeable descriptions of the same molecule.

This matters practically because searching for one may not surface pages about the other. If you find a supplier advertising tirzepatide under neither name, or referencing a brand that does not exist in the UK (Zepbound, for instance, is the US brand and is not sold or licensed here), treat that as a red flag. The licensed UK product is Mounjaro, and understanding the difference between the names is the first step toward navigating the market safely.

For context on what private treatment typically involves in terms of cost, the tirzepatide cost guide explains the pricing landscape and what a transparent private prescription should include.

How tirzepatide's dual mechanism sets it apart from older GLP-1 medicines

GLP-1 receptor agonists like semaglutide act on one receptor involved in appetite regulation and gastric emptying. Tirzepatide also activates the GIP receptor, a second gut-hormone pathway with a slightly different effect profile on satiety and fat metabolism. Activating both simultaneously appears to produce additive effects on weight, which is one reason the SURMOUNT-5 data showed greater average loss than semaglutide at its standard maintenance dose.

The practical upshot is that tirzepatide's mechanism is genuinely novel. The NICE appraisal of tirzepatide (TA1026) describes it as a dual receptor agonist and notes the indirect comparison evidence favouring it over existing GLP-1 medicines. That said, which medicine suits a given person is a clinical question, not a pharmacology one. Individual response, tolerance, existing conditions and other medicines all feed into that answer, and a prescriber is the right person to work through it.

UK eligibility and how NICE frames its recommendation

The licensed eligibility criteria sit in the Mounjaro SmPC: adults with a BMI of 30 or above, or 27 or above with at least one weight-related condition. Lower BMI thresholds can apply for certain ethnic backgrounds under UK guidance. NICE's recommendation in TA1026, published December 2024, adds a layer for NHS use: a BMI of 35 or above with at least one qualifying comorbidity, and a review point if less than 5% weight has been lost after six months at the highest tolerated dose.

Private prescribing follows the licensed criteria rather than the NICE commissioning thresholds. That distinction matters: many adults who meet the licence conditions but not the current NHS phased criteria access treatment through a regulated private pharmacy while NHS availability expands. If you are exploring weight-loss options and want to know where you sit, a consultation is the practical starting point. Our prescribers at our clinical team review each case personally, what a prescriber considers goes well beyond BMI alone.

Tirzepatide is a prescription-only medicine. Starting at 2.5 mg and titrating under clinical supervision is the licensed approach, and the prescriber decides the pace based on tolerability and response. If you want to understand what the tirzepatide 30 mg ceiling dose involves before committing to a full titration schedule, that conversation belongs in a consultation, not on a product page. If you want to understand what tirzepatide 10 mg and other mid-range steps involve before progressing to higher doses, that conversation belongs in a consultation, not on a product page. To check your eligibility and speak to a prescriber, the consultation is free and reviewed the same day.